Investor Webinar

Beyond Drug Development: A Better Life Sciences Business Model

Most biotech asks you to fund ten years of burn on one molecule and hope. NextGen Scientific runs it differently. A cancer drug program advances through the clinic while a consumer life sciences business sells product and books revenue today.

Co-Founder Jason West sits down with Ben DiScipio of Texture Capital to walk through where the company stands, what it is building next, and what that means for shareholders. Bring questions. The Q&A is open.

Date

Tuesday, August 25

Time

4:00 PM PT / 7:00 PM ET

Format

Online, with Q&A

Registration Seats open

Reserve your seat

Add your name and we will send the join link plus a calendar hold. Cannot attend on the day? Register anyway and we will send the replay.

On the agenda

Sixty minutes, five topics, one unfiltered Q&A

Management walks through the business, then opens the floor. Ask what you want to ask.

Where the business stands

Recent developments and the milestones the company has cleared since its last update.

Oncology and life sciences progress

Movement across the drug program and the rest of the portfolio, explained in plain terms.

Growth and commercial expansion

Which channels the company is pushing into next, and the thinking behind the sequence.

What comes next for shareholders

The road ahead, the near-term priorities, and how leadership measures its own progress.

Live Q&A with management

Your question goes straight to the people making the decisions.

Who you will hear from

Featured speakers

Jason West, JD, MBA

Co-Founder & Executive Vice President

Jason ran an oilfield chemical company through a nine-figure sale before turning to life sciences. He handles strategy, structure, and the legal side of how NextGen is built.

Former President, Jacam Chemical Company
Biology degree, Sterling College
Juris Doctor, Vermont Law School
MBA, Northwestern University

Ben DiScipio

Texture Capital

Ben works with private issuers on capital markets and investor relations at Texture Capital, a FINRA member broker-dealer. He moderates the session and keeps management on the questions investors actually care about.

Why this one is worth an hour

A biotech that already sells something

The industry standard is to raise money, spend it on research, and come back for more. NextGen inverted that. Revenue from the supplement line runs alongside the clinical work, which changes the math on how much dilution it takes to reach each milestone.

Two engines, one company

A supplement business moves product through Walmart.com and the company store. A cancer drug program moves through the clinic. One helps pay for the other.

Human data, not a slide deck

The lead oncology candidate has been through a Phase 1 study and has advanced into Phase 1B work at Virginia Commonwealth University. Management will walk through where that stands.

Operators who have finished before

Leadership has taken a company from build to sale. That experience shapes how this one is capitalized and how the exit path gets discussed.

The number that frames everything else on this call is [XXX], and Jason will explain exactly how the company got there.

Covered in the opening segment